This is now a contrarian view to think these molecular diagnostic can sustain top line growth after covid testing volume drops over time. Gss was growing well before covid and covid will only have accelerated its growth. I think this contrarian view will be profitable in the near future. Back the management who has been executing well time after time.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.36M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.0¢ | 34.5¢ | $93.63K | 271.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 4501 | 1 |
View Market Depth
| Last trade - 15.03pm 25/07/2025 (20 minute delay) ? |
| GSS (ASX) Chart |